Neuroimaging of Escitalopram in Autism Spectrum Disorder
Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the acute effects of escitalopram (Lexapro) on select brain networks during task-based functional magnetic resonance imaging (fMRI) in adolescent individuals with autism spectrum disorder (ASD). We hope to learn more about the acute effects of escitalopram and how it might be used to treat inflexible thinking or rigid-compulsive behavior that can be associated with restricted and repetitive behaviors in adolescents with ASD.
Participants will:
* Attend 3 visits to complete tests of thinking abilities and fill out surveys about their health and behavior
* Be randomly assigned to receive escitalopram at one of the first two visits after screening and a placebo at the other visit.
* Complete a reward-based task that tracks eye movement, either during MRI or in laboratory environment.